Modulating Neuroimmune Pathology for Transformative Therapeutics in Neuroscience
With hot BTKi and TREM2 readouts transforming AD & MS treatment landscapes, and an explosion of R&D innovation from astrocyte modulation, cGAS-STING pathway and JAK-STAT immunomodulation to peripheral immune targets, inflammasome targeting, complement inhibitors and GLP-1R, the neuroinflammation field is booming with investment and fresh energy.
Welcoming you to a niche community of 100+ biotech and pharma lab heads, directors and VPs from discovery research, translational and clinical development, search and evaluation and alliance management departments working across a breadth of pipelines, disease areas and targets, the 7th Neuroimmunology Drug Development Summit is the perfect opportunity to learn from each other, upskill yourself and your team and connect with your peers to fuel a new wave of transformative therapeutics in neuroscience.
Back Translating Clinical Insights to Early Neuroinflammatory R&D with More Predictive & Prognostic Biomarkers, 3D Cocultures, Novel Targets
Hear the latest BTKi efficacy and safety data in reducing disability accumulation in Multiple Sclerosis, including Sanofi’s Tolebrutinib, Novartis’ Remibrutinib, Biogen’s BIIB091 and Roche’s Fenebrutinib; and catch the latest TREM2 readouts with Novartis’ ATV:TREM2 and Vigil Neuroscience’s ALSP TREM2 to explore the future of anti-inflammatory agents play a role in the AD landscape
Refine your biomarker and clinical endpoint strategy by exploring established and exploratory markers of neuroimmunology disease progression including NFL, GFAP, NFH, YKL-40 oligoclonal bands for more confident translation of candidates through clinical development with PTC Bio, Alzheimer’s Drug Discovery Foundation, Takeda, EMD Serono and Neurocrin
Explore preclinical and clinical programs with novel targets and mechanisms to target the breadth of neuroinflammatory pathology including cGAS pathway with Ventus Therapeutics, brain delivery tech with Alector, JAK-STAT immunomodulation with Atalanta VA Medical Center, ImmunoBrain’s
immune checkpoint inhibition, peripheral-targeted agents with Takeda, EMD Serono and Discoveric Bio, inflammasome targeting with Sanofi, Inflammasome Therapeutics and University of Miami School of Medicine and cell therapies with Abata Therapeutics
Perfect 3D co-cultures and in vivo models to better reflect disease pathology and crosstalk in neuroinflammation with Sanofi, Biogen, Roche, Alchemab Therapeutics, Roche, National Institute of Aging (NIA), while refining multiomic driven discovery and drug development workflows with Eisai, Merck, Takeda, EMD Serono, Neurocrine Biosciences, Muna Therapeutics, Cognition Therapeutics, and University of Cincinnati
Who Will You Meet?
The 7th Neuroimmunology Drug Development Summit meeting unites 100+ key pharma and biotech leaders across translational medicine, clinical development, biomarker and target discovery, omics computational science, medical affairs and regulatory affairs.
From C-Level executives to clinical research scientists, leading figures in industry will be uniting this February to discover the latest unpublished data, hear heated panel discussions, and deep-dive workshops you won’t find anywhere else.
